“…Among the structurally related compounds, 1,2-dihydro-3 H -1,2,4-triazol-3-one and 4 H -benzo[ f ][1,2,4]triazolo[4,3- a ][1,4]diazepine are prominent. , Furthermore, this paper summarizes the top 100 triazole-related agents from clinical trials before 2020 (Figure ). Both 1,2,4-triazole and 1,2,3-triazole have garnered attention in drug design, particularly 1,2,4-triazole, which serves as a key pharmacophore extensively employed in the design of small molecule inhibitors such as antifungal agents and aromatase inhibitors. , Notably, these drug structures often feature 1,2,4-triazole at the terminal end, typically with substituents connected to the N1 position, such as letrozole, anastrozole, and fluconazole, primarily due to the mechanism of action involving the inhibition of cytochrome P450 (CYP450) and its family members by antifungal and aromatase inhibitors. , The lone pair electrons of the triazoles within the drug mimic a heme iron–nitrogen coordinate bond, thereby inhibiting the active sites of various enzymes within the CYP family. , In FDA-approved drug structures, 1,2,3-triazole is commonly utilized in dual orexin receptor antagonists (DORAs) for the treatment of insomnia, including daridorexant and suvorexant. , Despite the considerable interest in both 1,2,3-triazole and 1,2,4-triazole as potential anticancer pharmacophores for drug design, no anticancer drugs containing 1,2,3-triazole have been approved by the FDA, while several compounds containing 1,2,4-triazoles have entered clinical treatments. , 1,2,3-Triazole is favored in drug synthesis due to its straightforward synthetic methods, particularly with the widespread application of “click” chemistry and bioorthogonal coupling reactions in the field of medicinal chemistry, notably with 1,2,3-triazole serving as a linker in “click” chemistry-related drugs. − Attempts have been made to improve the shortcomings of traditional small molecule inhibitors by designing proteolysis targeting chimeras (PROTACs) and hydrophobic tagging (HyT) degraders as well as peptide–drug conjugates (PDCs) containing 1,2,3-triazole linkers using “click” chemistry. − Bioorthogonal coupling reaction methods enable real-time detection of PDCs, laying the foundation for further development and maturation of PDCs . Furthermore, 1,4-disubstituted 1,2,3-triazole scaffolds as amide bioisosteres, along with trans- amide bond isosteres, have found wide applications. , Replacing amide bonds with 1,4-disubstituted 1,2,3-triazoles in certain anticancer drugs such as vismodegib significantly improves the stability and even enhances antitumor activity .…”